Press Release Teva Presents New Phase 3 Efficacy, Safety And Tolerability Data From Solaris Trial Evaluating Tev ‘749 Olanzapine As A Once Monthly Subcutaneous Long Acting Injectable For Adult Patients Diagnosed With Schizophrenia
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Press Release Teva Presents New Phase 3 Efficacy, Safety And Tolerability Data From Solaris Trial Evaluating Tev ‘749 Olanzapine As A Once Monthly Subcutaneous Long Acting Injectable For Adult Patients Diagnosed With Schizophrenia is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of ...
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic ... Read More
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych ...
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the ... Read More
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California Teva will host a conference ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus